The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

In a recent article in the journal Antioxidants, researchers in Germany investigated whether cardiovascular drugs such as ...

Erri, S. and Oroszi, T. (2025) Isolated Systolic Hypertension in Geriatrics. International Journal of Clinical Medicine, 16, ...

The researchers found that people taking alpha-1 blockers – terazosin, doxazosin, and alfuzosin – were around 40% less likely to develop DLB than people taking other prostate drugs ...

The Food and Drug Administration (FDA ... at least 45 years old with OAB on BPH pharmacological therapy (eg, alpha blocker monotherapy or in combination with a 5-alpha reductase inhibitor).

Liver disease and oncology divisions have slightly underperformed but show potential for growth, especially with new acquisitions and upcoming drug approvals ... an HIV-1 integrase blocker ...

The alpha blocker is typically prescribed to manage a nuisance symptom. Here's why the FDA says patients and healthcare ...

Immune-histologically, IH cells are exclusively glucose transporter protein-1 positive.The ... and topical beta blockers as an effective treatment option resulted in a rapid shift away from systemic ...

Table 1 shows patient data including the type of α 1-blocker taken and other baseline ... Five patients had hypertension with anti-hypertension drugs, three had diabetes mellitus with anti ...

PURPOSE: Alpha blocker therapy has been successfully used ... All patients were treated with doxazosin, a selective alpha-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily.

Certain drugs can cause low blood pressure as a side effect. These include: All blood pressure medications, including beta blockers, alpha-blockers ... reducing sensitivity to glucagon-like peptide-1 ...